OOIR: Observatory of International Research

Papers

(The TQCC of European Journal of Health Economics is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Education and medication use later in life and the role of intelligence	85
Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication	61
Correction to: Geographic distribution of physicians in Portugal	40
Comparing the measurement properties of the EQ-5D-Y-3L, EQ-5D-Y-5L and CHU9D in children and adolescents: a measurement property study	30
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries	28
Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial	26
Patient-level cost analysis of subfertility pathways in the Dutch healthcare system	25
Pragmatic randomized controlled trial comparing a complex telemedicine-based intervention with usual care in patients with chronic conditions	24
Psychometric properties and general population reference values for PROMIS Global Health in Hungary	23
The hidden cost of sophistication: economic complexity and obesity	23
Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis	22
Workload and short sickness absences in a cohort of Finnish hospital employees	21
From test to rest: evaluating socioeconomic differences along the COVID-19 care pathway in the Netherlands	21
Expensive today but cheaper tomorrow: lifetime costs of an active middle ear implant compared to alternative treatment options	20
Cost awareness among intensivists in their daily clinical practice: a prospective multicentre study	19
Primary care services and emergency department visits in blended fee-for-service and blended capitation models: evidence from Ontario, Canada	19
Nothing about us, without us? A reflection on and call for involving children in the process of valuing child health	19
Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan	19
Prescription opioids and economic hardship in France	19
Replay to: Comparison of EQ-5D-5 L and EORTC QLU-C10D utilities in gastric cancer patients	19
Setting incentives right with long-term risk adjustment	18
Comparing EQ-5D-5L and SF-6Dv2 utilities with QLU-C10D utilities in hematologic cancer patients	18
Health-related quality of life in patients with alcohol use disorder: comparing instruments and mapping from clinical measures to preference-based measures	18
Economic assessment of abemaciclib for the adjuvant treatment of luminal HER2- breast cancer from the perspective of the Spanish health system	17
Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade	17

Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma	16
Multinational stakeholder engagement to inform future development and refinement of the EuroQol toddler and infant populations (EQ-TIPS)	16
Informing decisions in light of parameter uncertainty – an economic evaluation of the adjuvanted recombinant herpes zoster vaccine in Sweden	16
The causal effect of catastrophic health expenditure on poverty in Poland	16
Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands	15
Correction: AOTMiT reimbursement recommendations compared to other HTA agencies	15
Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis	15
The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands	15
Benefits beyond health in the willingness to pay for a quality-adjusted life-year	15
Can competition improve hospital quality of care? A difference-in-differences approach to evaluate the effect of increasing quality transparency on hospital quality	15
Breaking the rules: decision-making under absolute resource constraints	15
On spillovers in economic evaluations: definition, mapping review and research agenda	15
Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data	15
The trade-off between health system resiliency and efficiency: evidence from COVID-19 in European regions	14
How perceptions of bone marrow donation costs affect donation behavior: survey evidence from a large donor registry	14
Sex differences in care complexity and cost of cardiac-related procedures as a basis for improving hospital payments systems	14
Analyzing nurses’ decisions to leave their profession—a duration analysis	14
Do EQ-5D-Y-3L value sets have common properties, and how do they compare to EQ-5D-5L value sets?	14
Costs attributable to hypercholesterolemia in a single period and over the life cycle	13
Estimating loss in capability wellbeing in the first year of the COVID-19 pandemic: a cross-sectional study of the general adult population in the UK, Australia and the Netherlands	12
The goal of risk equalization in regulated competitive health insurance markets	12
The impacts of working from home on individual health and well-being	12
Is next generation sequencing for the diagnosis of rare diseases worth its cost? A user-based approach to valuation	12
Economic value of diastasis repair with the use of mesh compared to no intervention in Italy	12
Adverse selection and consumer inertia: empirical evidence from the Dutch health insurance market	11
Healthcare costs of foodborne diseases in the United States: an analysis using electronic health records	11
Time value of informal care of people with alzheimer’s disease in Spain: a population-based analysis	11
A principled approach to non-discrimination in cost-effectiveness	11
Is ultra-hypo-fractionated radiotherapy more cost-effective relative to conventional fractionation in treatment of prostate cancer? A cost–utility analysis alongside a randomized HYPO-RT-PC trial	11
The impact of ambulatory care spending, continuity and processes of care on ambulatory care sensitive hospitalizations	11
The social value of gambling: surplus estimates by gambling types for France	11
Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis	10
Modeling European health systems: an ideal chain of services	10
A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots	10
The attractiveness of jobs in the German care sector: results of a factorial survey	10
Does medial tourism promote growth in healthcare sector?	10
Valuation of the EQ-5D-3L in Jordan	10
Do mobile hospital teams in residential aged care facilities increase health care efficiency: an evaluation of French residential care policy	10
Pharmacy cost groups for the German morbidity-based risk compensation scheme	10
Estimating QALYs in adults with cerebral palsy: mapping the San Martin scale to the EQ-5D-5L for economic evaluation	10
Changes in spending, quality indicators, and provider experiences following the introduction of a population-based payment model in dutch primary care: a mixed methods evaluation	10
Demographic and health impacts of women’s bodily autonomy: switching prescription requirements for emergency contraceptives	10
Tenders for generics and biosimilars: a challenging purchasing policy	9
Significant healthcare burden and life cost of spinal muscular atrophy: real-world data	9
Alcohol prices, the April effect, and the environment, in violence-related injury in England and Wales	9
The ACA Medicaid expansions and abortion rates among young adults	9
Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2021: an observational study from the French national health data system	9
Preferences for COVID-19 epidemic control measures among French adults: a discrete choice experiment	9
Scales and size-quality outcomes in adult learning disability residential care: evidence from the UK	9
Validation of the PAM-13 instrument in the Hungarian general population 40 years old and above	9

Modeling the potential efficiency of a blood biomarker-based tool to guide pre-hospital thrombolytic therapy in stroke patients	9
Does chronic disease coverage for outpatient care affect healthcare utilization and expenditures in China? Evidence from an administrative claim dataset	9
Do we care about high-cost patients? Estimating the savings on health spending by integrated care	9
Survival analysis of cancer patients in Portugal following the reference centre model implementation	8
Cost-utility of cochlear implantation in single-sided deafness and asymmetric hearing loss: results of a randomized controlled trial	8
The pass-through of excise taxes to market prices of heated tobacco products (HTPs) and cigarettes: a cross-country analysis	8
Challenges for health systems seeking to embrace virtual health care for population health	8
Obtaining preference scores for an abbreviated self-completion version of the Teen-Addiction Severity Index (ASC T-ASI) to value therapy outcomes of systemic family interventions: a discrete choice ex	8
Determinants of willingness to pay for health services: a systematic review of contingent valuation studies	8
Costs of productivity loss up to two years after ischaemic stroke	8
Assessment of health state utilities associated with adult and pediatric acid sphingomyelinase deficiency (ASMD)	8
Supply-side solutions targeting demand-side characteristics: causal effects of a chronic disease management program on adherence and health outcomes	8
Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality	8
Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors	8
The link between physician motivation and care	7
Healthcare costs of diabetic foot disease in Italy: estimates for event and state costs	7
Does diagnostic testing always decrease antibiotics prescriptions?	7
The health and long-term care costs in the last year of life in The Netherlands	7
Inpatient care utilisation and expenditure associated with objective physical activity: econometric analysis of the UK Biobank	7
How are patient inputs considered in HTA? A thematic document analysis of NICE ultra-rare disease appraisals	7
Self-interest, positional concerns and distributional considerations in healthcare preferences	7
Economic evaluation on dental caries preventive interventions for Australian children using a priority-setting approach	7
Trends and drivers of pharmaceutical expenditures from systemic anti-cancer therapy	7
Disclosing the ‘Big C’: what does cancer survivorship signal to employers?	7
Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis	7
Personnel shortages and the provision of long-term care: an empirical analysis of German nursing homes	7
Cost-effectiveness of two online interventions supporting self-care for eczema for parents/carers and young people	7
Referring physicians' intention to use hospital report cards for hospital referral purposes in the presence or absence of patient-reported outcomes: a randomized trial	7
Unravelling heterogeneity in efficiency measurements: a case study of public hospitals in Spain	7
Modeling European health systems: a theoretical exercise	7
Seeking efficiency gains outside drugs and diagnostics	6
Long-term costs associated with healthcare use of people with cancer in Scotland	6
One week versus three to five weeks of plaster cast immobilization for nonreduced distal radius fractures, a cost effectiveness analysis embedded in a stepped wedge cluster randomized controlled trial	6
Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment	6
Health state utilities associated with X-linked retinitis pigmentosa (XLRP)	6
Time preferences and COVID-19 vaccination uptake	6
A critical review of the use of R2 in risk equalization research	6
Assessing Taiwan’s pay-for-performance program for diabetes care: a cost–benefit net value approach	6
Does health technology assessment compromise access to pharmaceuticals?	6
The performance of the EQ-HWB-S as a measure of quality-of-life of caregivers in families that have experienced adverse events	6
Comparing EQ-5D-5L, PROPr, SF-6D and TTO utilities in patients with chronic skin diseases	6